Vertebrate Antibodies Ltd (VAL) produces a broad range of high-quality antibodies specific to a number of mammalian species. Through extensive collaborative studies, a large panel of monoclonal antibodies have been developed for novel targets. Antibodies are usually validated by ELISA, Immunoblotting and immunohistochemistry on multi-normal and multi-tumour tissue microarray (see validation platform). A significant number of antibodies has been published in peer-reviewed journals. Additionally, the clinical significance of the developed antibodies has been assessed on a large cohort of tumour tissues. Due to the extensive bioinformatics analysis performed by the VAL team, antibodies are designed in such a way to cover multiple mammalian species increasing the products value and providing tools to species of economic and research importance. This will broaden their application in the health and veterinary fields as well as for specific research areas.